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Edited by Angel NebredaAbstract Most tumor cells attain their immortality by reacti-
vating telomerase. We report here the telomerase inhibitory po-
tential of chimeric oligonucleotides composed of a 13mer
antisense sequence targeting the telomerase RNA template re-
gion and a (s4dU)n moiety at its 3
0 or 5 0-end. The increase of
the thiolated chain length enhances the telomerase inhibitory po-
tential, but decreases speciﬁcity, indicated by HIV reverse trans-
criptase inhibition. Chimeras with 5 0 (s4dU)ns were more potent
inhibitors than the antisense alone or the 3 0 modiﬁed ones. Cy5-
labeled (s4dU)4AS and (s
4dU)8AS proved the internalization of
the oligonucleotides, raising the possibility to be tested as cellu-
lar anti-telomerase agents.
 2005 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Telomerase, a ribonucleoprotein complex that includes an
RNA template (hTR) and a catalytic subunit (hTERT) with
reverse transcriptase activity, is responsible for telomere pro-
tection and maintenance [1]. This enzyme binds the 3 0 over-
hang of the telomeric DNA and extends it by copying its
RNA-template that is complementary to the hexameric unit
of the DNA telomeric repeat sequence (TTAGGG in verte-
brates) [2]. Most of the human cancer cells exhibit measurable
telomerase activity in contrast to normal human adult somatic
cells [3] with a few exceptions like stem cells of renewable tis-
sues and activated lymphocytes [4]. This relative speciﬁc
expression pattern makes this ribonucleoprotein a rational tar-
get of antineoplastic chemotherapy, with considerations about
the long lag phase before the onset of cell death as a result of
critical telomere shortening. However, in some cases cell death
occurs faster than one might predict based on the rate of telo-
mere shortening, suggesting additional roles of telomerase in
protecting cells against apoptosis [5].*Corresponding author. Fax: +36 52 314989.
E-mail address: aradi@indi.biochem.dote.hu (J. Aradi).
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doi:10.1016/j.febslet.2005.01.041There are several well-established classes of telomerase
inhibiting compounds: small catalytic-inhibitor molecules,
reverse transcriptase inhibitors, compounds that stabilize the
folding of telomeric G-rich single-stranded DNA into G-
quadruplex and oligonucleotide-type inhibitors [6].
hTR is a favorable target for antisense strategies because
being a template, means exceptional accessibility. Previous
studies have shown that anti-template phosphorothioate-
modiﬁed oligonucleotides show competitive behavior regard-
ing primer-substrates, what suggested their interaction with a
protein motif, termed primer binding site, which normally
binds to DNA to be elongated [7]. Matthes and Lehmann were
the ﬁrst, who proposed the evaluation of anti-telomerase chi-
meric oligonucleotides that contain a moiety targeting the pri-
mer binding site and a sequence against the RNA as well.
These ﬁndings evoke our idea of the rational design of active
molecules which contain, beside the well-established anti-tem-
plate sequence, a chemically modiﬁed oligonucleotide moiety
known to interact with reverse transcriptases, thus presumably
also with the catalytic subunit of telomerase. Chemical modiﬁ-
cation of telomerase inhibiting oligonucleotides meant usually
altered backbones like N3 0 ﬁ P5 0 phosphoramidate or thio-
phosphoramidate [8], phosphorothioate-modiﬁed DNA [9],
peptide nucleic acid [10], 2 0-O-alkyl RNA [11,12], and were
mainly addressed to improve biological properties. To our
knowledge, trials with base-modiﬁed oligonucleotide deriva-
tives or base-modiﬁed chimeric molecules have not been made
before. We report here the telomerase inhibiting activity of a
novel type of chimeric oligonucleotides, which are composed
of an antisense sequence, directed against the template region
of hTR and a base-modiﬁed (s4dU)n moiety. The aim of this
trial was to evaluate if the anti-telomerase activity of the clas-
sical oligonucleotide can be enhanced by a modiﬁcation serv-
ing the above-mentioned ‘‘dual target’’ strategy, without
excluding the possibility of further chemical improvement
using backbone modiﬁcations.2. Materials and methods
2.1. Partial puriﬁcation of human telomerase
The partially puriﬁed human telomerase was prepared from HL-60
cells with slight modiﬁcations of the previously described protocol
[13]. Main steps of the protocol are: precipitation with 40% ammonium
sulfate and anion-exchange chromatography on DEAE–Sepharoseblished by Elsevier B.V. All rights reserved.
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1412 I. Tarkanyi et al. / FEBS Letters 579 (2005) 1411–1416column (Pharmacia). After chromatography, active fractions were
pooled, dialyzed and re-puriﬁed on DEAE–Sepharose column. Telo-
merase inhibition studies with the pooled extract after the ﬁrst and sec-
ond chromatography gave the same results.
2.2. Oligonucleotides
Chemically modiﬁed oligonucleotides used for inhibition studies,
Cy5-labeled molecules and primers used in TP-TRAP assay were syn-
thesized by standard phosphoramidite chemistry and puriﬁed using an-
ion-exchange chromatography as described previously [13,14]. (s4dU)n
and the chimeras were prepared by H2S treatment (10 days at 55 C) of
the corresponding (dC)n or (dC)n-extended AS/SCR [15]. The starting
oligonucleotide of 3 0-blocked (s4dU)8AS was synthesized using 3 0-
Spacer C3 CPG (Glen Research).OH
Fig. 1. Structure of the monomer unit of (s4dU)n (4-thio-deoxyur-
idylate).2.3. Telomerase activity measurement
Telomerase activity was measured using a modiﬁcation of the TP-
TRAP assay [13]. Brieﬂy, inhibitor oligonucleotides (in various con-
centrations at a range between 2 nM and 4 lM, ﬁnal concentrations)
were preincubated at 25 C with the partially puriﬁed telomerase en-
zyme, then the enzyme reaction was initiated by the addition of the
MTS substrate primer (25 pmol) [AGCATCCGTCGAGCAGAGTT]
as well as dATP, dCTP, dGTP (50 lM), dTTP (2 lM), 0.5 lCi
[Me-3H]dTTP (Amersham) and 2.25 U JumpStart Taq (Sigma) and re-
verse primers.
For telomerase-mediated extension of MTS primer, reaction mix-
tures were incubated at 30 C for 10 min, heated to 95 C for 2 min,
followed by the PCR-ampliﬁcation of the extension products. Labeled
ampliﬁcation products were collected by ﬁltration and quantiﬁed by li-
quid scintillation counting. Measurements were performed at least as
duplicates. Activity was plotted as a function of concentration of the
added inhibitor using GraphPad Prism 2.01 software and IC50 param-
eters were determined graphically from these.0
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Measurement of reverse transcriptase activity was performed as we
described earlier [15]. Inhibitors were preincubated with 0.1 U HIV re-
verse transcriptase (Amersham) in a reaction mixture containing
[Me-3H]dTTP. Reverse transcriptase action was primed by adding
the template primer, followed by incubation at 37 C for 1 h. Radioac-
tive products were collected and measured as in the TP-TRAP-assay.
2.5. Oligonucleotide uptake studies
A431 human planocellular carcinoma cells were allowed to adhere
overnight, then transfected with Oligofectamine Reagent (Invitrogen)
and Cy5-labeled oligonucleotides [Cy5-X4AS and Cy5-X8AS] at
200 nM concentration according to the manufacturers directions. After
4 h of incubation cells were washed with PBS, ﬁxed/permeabilized using
4% formaldehyde and 0.2%TritonX-100 in PBS, and incubated (15 min
at room temperature) with 30 lg/ml Alexa Fluor 488-tagged 528 mono-
clonal antibodies against epidermal growth factor receptors (EGFR).
Cells were then washed and stained with ethidium bromide (0.5 lg/
ml). The cellular distribution of Cy5-labeled oligonucleotides was stud-
ied by confocal laser scanning microscopy (Zeiss LSM 510). The con-
tours of the plasma membrane and the nucleus were visualized by
ﬂuorescent anti-EGFR antibodies (A431 cells are known to express
EGFR in high number [16]) and ethidium bromide as described above.
For the excitation of Alexa Fluor 488, the 488-nm line of anAr ion laser,
for ethidium, a 543-nm HeNe laser and for Cy5, a 633-nm HeNe laser
were used. Fluorescence emission was detected through 500–550 nm
and 560–610 nm bandpass and 650 nm longpass ﬁlters, respectively.
With a Plan-Apochromat 63· oil immersion objective image stacks of
0.6 lm thick optical sections were collected.0 10 20 30
preincubation time (min)
Fig. 2. Eﬀect of preincubation time on the inhibitory activity of
X16AS. Black diamonds indicate the telomerase activity (represented
by the DPM values) measured with TP-TRAP assay in the presence of
40 nM X16AS. (This generates analyzable data in contrast to the
utilization of a much weaker or a much stronger inhibitor.) Empty
circle represents telomerase control without inhibitor.3. Results
3.1. Eﬀect of 3 0 or 5 0 attached (s4dU)n on the telomerase
inhibiting potential of a 13mer antisense oligonucleotide
The (s4dU)35 (abbreviated as X35; X represents a 4-thio-
deoxyuridylate unit, structure shown in Fig. 1) was a compet-itive inhibitor of HIV-RT and human telomerase with respect
to the functioning RT template-primer and telomerase sub-
strate primer [13,15]. The inhibitory features of X35 prompted
us to develop chimera oligonucleotides, composed of a 13mer
phosphodiesther antisense sequence (AS), designed to target
hTR template region and a 3 0 or 5 0 Xn (n = 4, 8, 16 and 24)
moiety, which is thought to interact with the protein subunit
of human telomerase. First we determined the IC50 values
for the inhibitors on partially puriﬁed telomerase using the
TP-TRAP assay.
Since telomerase inhibiting potential of X35 was signiﬁcantly
aﬀected by preincubation of the inhibitor with the enzyme [13],
we tested the eﬀect of various preincubation times (0–30 min)
on inhibition (Fig. 2), and chose 10 min for the IC50 studies,
because this period was measured to be obligatory and suﬃ-
cient for the chimeras to exhibit maximal inhibitory potential.
Considering the fact that oligonucleotides are relatively large
molecules that need to hybridize to the target sequence to
act as inhibitors this is not an unusual phenomenon, under-
lined also by the experimental layout for telomerase inhibition
studies of other oligonucleotides [10,12].
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Fig. 3. Dose–response curve for inhibition of telomerase with
(s4dU)8AS (ﬁlled circles) or AS(s
4dU)8 (empty circles). After preincu-
bation of the inhibitors at diﬀerent concentrations with the partially
puriﬁed telomerase, enzyme activity (represented by the DPM values)
was measured by TP-TRAP assay. The square represents the results of
the control experiments for the PCR-step using (s4dU)8AS or
AS(s4dU)8 at 200 nM. Inhibitors added after the telomerase reaction
but before the PCR ampliﬁcation proved that measured eﬀect is due to
telomerase inhibition.
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with an IC50 of 174.2 nM (Table 1). Sequence speciﬁcity of
AS-mediated inhibition was proven by scrambled control
(IC50 [SCR] > 4000 nM; Table 1).
The chimeras were prepared by thiolation of the (dC)n-ex-
tended AS. Although thiolation procedure was not expected
to cause chemical modiﬁcation [17], to ensure that the AS com-
ponent remains unaltered, we thiolated a sample of AS,
according to the standard procedure. Comparison of the
UV-spectra and the inhibitory parameters, before or after
the thiolation, gave the same results (data not shown).
Antisense oligonucleotides with 5 0 (s4dU)ns were more po-
tent inhibitors either than the antisense alone or the 3 0-modi-
ﬁed ones (Table 1 and Fig. 3 as an example of a dose–
response curve). Increasing length of the thiolated moiety in-
creased the telomerase inhibitory potential up to
IC50 = 24 nM, when 16 or 24 modiﬁed bases were attached
to the 5 0-end. However, the inhibitory activity of the 3 0 X4
and X8 modiﬁed oligonucleotides were less than that of the
13mer AS. A further increase of the length of the 3 0 modiﬁed
moiety increased the inhibition close to the same extent than
the 5 0 modiﬁed counterparts (IC50 [ASX24] = 31.3 nM).
Control experiments included oligonucleotides comprising
just the chemically modiﬁed component [Xn], scrambled mole-
cules with 5 0 (s4dU)ns to prove sequence speciﬁty [(X)nSCR]
and parent compounds for chemically modiﬁed chimeras
[(C)nAS] to evaluate the role of the thiolated moiety. Xn
homo-oligomeres inhibited telomerase in chain length depen-
dent manner, similarly as observed on HIV RT [15], where
25–40mers were shown to be active. Derivates containingTable 1
Inhibition of telomerase by oligonucleotides
Name Sequence IC50 ± SD (nM)
AS AGTTAGGGTTAGA 174.2 ± 14.1
(X)4AS (s
4dU)4AGTTAGGGTTAGA 134.2 ± 16.9
(X)8AS (s
4dU)8AGTTAGGGTTAGA 38.2 ± 12.4
(X)16AS (s
4dU)16AGTTAGGGTTAGA 24.0 ± 3.6
(X)24AS (s
4dU)24AGTTAGGGTTAGA 24.3 ± 3.6
AS(X)4 AGTTAGGGTTAGA(s
4dU)4 292.4 ± 10.6
AS(X)8 AGTTAGGGTTAGA(s
4dU)8 308.1 ± 13.7
AS(X)16 AGTTAGGGTTAGA(s
4dU)16 112.4 ± 25.5
AS(X)24 AGTTAGGGTTAGA(s
4dU)24 31.3 ± 13.5
(X)4 (s
4dU)4 >4000
(X)8 (s
4dU)8 2974.1 ± 365.6
(X)16 (s
4dU)16 310.9 ± 76.0
(X)24 (s
4dU)24 116.6 ± 8.1
SCR GTGATGATGATGA >4000
SCR(X)4 GTGATGATGATGA(s
4dU)4 2127.1 ± 509.9
SCR(X)8 GTGATGATGATGA(s
4dU)8 154.4 ± 19.6
SCR(X)16 GTGATGATGATGA(s
4dU)16 65.7 ± 9.2
SCR(X)24 GTGATGATGATGA(s
4dU)24 25.3 ± 11.3
(C)4AS (C)4AGTTAGGGTTAGA 2760.1 ± 617.4
(C)8AS (C)8AGTTAGGGTTAGA >4000
(C)16AS (C)16AGTTAGGGTTAGA –
***
(C)24AS (C)24AGTTAGGGTTAGA 417.1 ± 66.2
(X)8ASsp (s
4dU)8AGTTAGGGTTAGA spacer 28.3 ± 5.1
Shown are synthesized chimeras with 30 or 50 (s4dU)n and respective
controls.
***telomerase activity was elevated by C16AS.scrambled sequences showed weak inhibition when the modi-
ﬁed part was short, but the IC50 for X24SCR reached the level
of X24AS. 5
0 cytidilates almost abolished the anti-telomerase
activity of the AS sequence. Surprisingly, C16AS increased
the telomerase activity substantially. As this augmentation
was only present in the case of C16AS, we suggest that it might
be the result of an aptamer-like eﬀect, underlined by the fact
that base pairing between cytidilates and the G-rich AS-part
is very likely.
3.2. Eﬀect of blocking the 3 0-OH of XnAS
The (X)nAS oligonucleotide inhibitors carry telomeric se-
quences at their 3 0-end, therefore they can be utilized as telo-
merase substrates elongated by telomeric repeats. To
evaluate if the extension of the inhibitors has a role in their
function, we used oligonucleotides carrying 3 0 propyl-group
as blocker of the 3 0-function [(X)8ASsp]. As demonstrated in
Table 1, we did not see a diﬀerence between the IC50 of
(X)8AS and (X)8ASsp (IC50[X8AS]: 38.2 nM and IC50 [X8ASsp]:
28.3 nM ± 5.1).
3.3. Speciﬁcity of chimeric oligonucleotides for telomerase
To exclude the possibility that oligonucleotides aﬀect the
Taq-polymerase, control experiments were run with 200 nM
of the appropriate inhibitors, which were added after the telo-
merase reaction, but before the PCR. Ampliﬁcation was barely
aﬀected by the presence of the inhibitors (Fig. 3 and data not
shown), indicating that the eﬀects observed in the TP-TRAP-
assay were due to the inhibition of telomerase.
Speciﬁcity of the oligonucleotides was also proven on HIV
reverse transcriptase, which shares common motifs with
hTERT [18]. We tested all synthesized oligonucleotides in re-
verse transcriptase assays using them at concentrations that
corresponded to the IC90s for telomerase. Chimeras with long
modiﬁed moieties turned out not to be speciﬁc for telomerase
(Fig. 4), as suggested by the 90% inhibition of RT at their IC90
0.0
20.0
40.0
60.0
80.0
100.0
120.0
A
S
X
4A
S
X
8A
S
X
16
A
S
X
24
A
S X
4
X
8
X
16
X
24
SC
R
X
4S
C
R
X
8S
C
R
X
16
SC
R
X
24
SC
R
A
SX
4
A
SX
8
A
SX
16
A
SX
24
C
4A
S
C
8A
S
C
16
A
S
C
24
A
S
H
IV
 R
T-
a
ct
iv
ity
(%
)
Fig. 4. Inhibition of HIV reverse transcriptase by anti-telomerase oligonucleotides. Applied concentrations correspond to the IC90 (dashed line
indicates 10% activity) of the inhibitor for partially puriﬁed telomerase or 4 lM, the maximal tested concentration in the TP-TRAP assay (in cases
when calculated IC90 would have been higher than this concentration). RT-activity assays were performed in duplicate, reported values are averages,
error bars correspond calculated standard deviations (±).
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weak inhibitors of the viral reverse transcriptase.
3.4. Cellular uptake of oligonucleotide inhibitors
The eﬃciency of antisense strategies is highly dependent on
the cellular delivery of oligonucleotide agents. It was found
that X35 does not penetrate into the cell (Horvath, A.,
Aradi, J., unpublished data), suggesting that we may face sim-
ilar problem with X-extended anti-telomerase oligonucleo-
tides. Therefore we examined the cellular uptake of the
inhibitors with confocal laser scanning microscopy using
Cy5-labeled oligonucleotides. Chosen candidates were X4AS
and X8AS, since their inhibition characteristics seem to be
the most attractive for anti-telomerase strategies in cellular
systems. We treated A431 cells with 200 nM Cy5-X4AS or
Cy5-X8AS and Oligofectamine, a lipid-type carrier. Inhibitor-
transfected cultures showed no morphological changes and
no signs of acute cytotoxicity with light microscopy compared
with the control samples treated only with Oligofectamine.Fig. 5. Optical sections of A431 cells treated with Cy5-tagged X8AS. Oligonuc
as well, showing a perinuclear enrichment. The nucleus was stained by ethid
were labeled by Alexa Fluor 488-tagged 528 monoclonal antibodies to visuaPictures obtained with the confocal microscope after stain-
ing the plasma membrane and nuclei, clearly showed the inter-
nalization of the chemically modiﬁed oligonucleotides (Fig. 5).
Labeled inhibitors were found in the cytosol and in the nucleus
as well, with a characteristic perinuclear enhancement. Cell line
293T was also examined (pictures not shown) and showed sim-
ilar intracellular oligonucleotide distribution.4. Discussion
The inhibitory potential of the above-presented chimeric oli-
gonucleotides seem to support the dual targeting hypothesis,
namely that AS sequence of XnAS inhibitors forms double he-
lix with the template region of hTR, while Xn interacts with the
protein part (Fig. 6) and the two interactions enhance each
other. However, structural proves will need detailed experi-
ments. Evaluation of primer-enzyme interactions proved that
beside the interaction with the 3 0 of the primer at the catalyticleotides (Cy5-X8AS, blue) are present in the cytoplasm and the nucleus
ium bromide (EtBr, red). Epidermal growth factor receptors (EGFR)
lize the plasma membrane (green). Scale bar: 10 lm.
3’ 5’
hTR
hTERT
I I II I
I I I I I II
3’
5’
Primer binding site
Antisense component(s dU)  component4 n hTR template region
Fig. 6. Putative mechanism of XnAS inhibitors. AS forms a double
helix with the template region of hTR, and Xn interacts with the
protein part responsible for primer (telomerase substrate) binding.
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ciﬁc contact with the protein, which seems to inﬂuence binding
aﬃnity as well as rate of polymerization [19]. It seems to be
possible that the protein surface that normally interacts with
the 5 0 of its primer-DNA has a high aﬃnity for thiolated oligo-
nucleotides too, and their binding impairs the catalytic activity
or inhibits the interaction of the telomerase with the natural
DNA-substrate. The fact that blocking of the 3 0 end has no ef-
fect on inhibition suggests that extension of the chimeric mol-
ecules has no crucial role in the mechanism, although we
cannot exclude that non-blocked inhibitors might be elon-
gated.
In case of ASXn type of inhibitors, the hybridization to the
RNA and the binding of the chemically modiﬁed part to the
protein (presumably to other sites than 5 0-extended ones) is
also possible. The ‘‘antisense’’-contact to the RNA is slightly
weakened when short thiolated moiety is attached to the 3 0-
end, indicating that they may disturb the interaction of the
AS with the target sequence. The similar inhibitory activity
of X24 modiﬁed antisenses (3
0 or 5 0) indicates that these long
inhibitors may not follow the proposed mode of action. This
conclusion was also supported by the potent inhibitory poten-
tial of the (X)24SCR which is not able to form base pairs with
the hTR template sequence (IC50s of (X)24AS, AS(X)24 and
(X)24SCR did not diﬀer essentially). Moreover, these derivates
are not speciﬁc, since they inhibited HIV RT with similar
parameters. These ﬁndings can be explained by the property
of the chemically modiﬁed oligonucleotides to inhibit DNA-
polymerases in a sequence nonspeciﬁc manner, since 37mer
chimeras (X24 modiﬁed antisenses and scramble) reach the
length reported to have maximal inhibitory activity
(30–40mers [15]). In contrast, X24 (as shown by its IC50 in
Table 1) is too short to exert full sequence nonspeciﬁc
inhibition.
Considering is the physico-chemical nature of the interaction
of thiolated oligonucleotides with the protein, there are two
likely modes: (a) hydrophobic interaction, due to the hydro-
phobic character of the 4-thiono group, or (b) disulﬁde bond
formation between properly localized cysteinyl side chains on
hTERT surface and reactive –SH, formed on the (s4dU) base
due to tautomeric conversion. The latter, covalent interaction
between proteins and (s4dU) containing oligonucleotides is
chemically feasible and was proven (Horvath, A., Aradi, J.,
unpublished data).
Since telomerase exerts its function as a DNA-polymerase
obligatory in the nucleus, the observed nuclear uptake of
our chimeric oligonucleotides seems to be promising. The per-
inuclear portion might correspond to the dissociating lipid-
oligonucleotide complexes [20]. Experiments to evaluatehTERT subcellular localization in immortal cell lines showed
that hTERT is immunologically detectable not only in nuclei
but also in the cytoplasm [21]. Strong Cy5 signals detected in
the cytoplasm may also correspond, at least to some degree,
to oligonucleotides bound to the cytoplasmic telomerase.
In conclusion, the properties of the novel family of chimeric
oligonucleotides, described here for the ﬁrst time, indicate that
development of such molecules might be a favorable anti-telo-
merase strategy since further improvement in inhibitory
parameters and intracellular properties are possible (for e.g.,
by introducing various backbone modiﬁcations). Moreover,
following the idea of dual interaction, using the presented
chemically modiﬁed chimeras as lead compounds, could pro-
vide new data in the biology of telomerase inhibition.Acknowledgments: This work was supported by OTKA T-038163
(Hungary) research Grant, BIO-00032/2001 Biotechnology Grant,
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